Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 160

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma

Open access
Saha, Supriya K., Gordan, John D., Kleinstiver, Benjamin P., Vu, Phuong, Najem, Mortada S., Yeo, Jia-Chi, Shi, Lei, Kato, Yasutaka, Levin, Rebecca S., Webber, James T., Damon, Leah J., Egan, Regina K., Greninger, Patricia, McDermott, Ultan, Garnett, Mathew J., Jenkins, Roger L., Rieger-Christ, Kimberly M., Sullivan, Travis B., Hezel, Aram F., Liss, Andrew S., Mizukami, Yusuke, Goyal, Lipika, Ferrone, Cristina R., Zhu, Andrew X., Joung, J. Keith, Shokat, Kevan M., Benes, Cyril H., Bardeesy, Nabeel·2016·Cancer Discovery

Abstract

Intrahepatic cholangiocarcinoma (ICC) is an aggressive liver bile duct malignancy exhibiting frequent isocitrate dehydrogenase (IDH1/IDH2) mutations. Through a high-throughput drug screen of a large panel of cancer cell lines, including 17 biliary tract cancers, we found that IDH mutant (IDHm) ICC cells demonstrate a striking response to the multikinase inhibitor dasatinib, with the highest sensitivity among 682 solid tumor cell lines. Using unbiased proteomics to capture the activated kinome and CRISPR/Cas9-based genome editing to introduce dasatinib-resistant “gatekeeper” mutant kinases, we identified SRC as a critical dasatinib target in IDHm ICC. Importantly, dasatinib-treated IDHm xenografts exhibited pronounced apoptosis and tumor regression. Our results show that IDHm ICC cells have a unique dependency on SRC and suggest that dasatinib may have therapeutic benefit against IDHm ICC. Moreover, these proteomic and genome-editing strategies provide a systematic and broadly applicable approach to define targets of kinase inhibitors underlying drug responsiveness. Significance: IDH mutations define a distinct subtype of ICC, a malignancy that is largely refractory to current therapies. Our work demonstrates that IDHm ICC cells are hypersensitive to dasatinib and critically dependent on SRC activity for survival and proliferation, pointing to new therapeutic strategies against these cancers. Cancer Discov; 6(7); 727–39. ©2016 AACR. This article is highlighted in the In This Issue feature, p. 681

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-15-1442

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 160

Metadata

Authors
Saha, S. K., Gordan, J. D., Kleinstiver, B. P., Vu, P., Najem, M. S., Yeo, J.-C., Shi, L., Kato, Y., Levin, R. S., Webber, J. T., Damon, L. J., Egan, R. K., Greninger, P., McDermott, U., Garnett, M. J., Jenkins, R. L., Rieger-Christ, K. M., Sullivan, T. B., Hezel, A. F., Liss, A. S., Mizukami, Y., Goyal, L., Ferrone, C. R., Zhu, A. X., Joung, J. K., Shokat, K. M., Benes, C. H., & Bardeesy, N.
Venue
Cancer Discovery
Published
2016-06-30
Volume
6
Issue
7
Pages
727-739
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W2408652783
Cited by
160
References
11
FWCI
20.25
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma. https://app.cochat.ai/papers/10.1158/2159-8290.cd-15-1442
The paper
Saha, S. K., Gordan, J. D., Kleinstiver, B. P., Vu, P., Najem, M. S., Yeo, J.-C., Shi, L., Kato, Y., Levin, R. S., Webber, J. T., Damon, L. J., Egan, R. K., Greninger, P., McDermott, U., Garnett, M. J., Jenkins, R. L., Rieger-Christ, K. M., Sullivan, T. B., Hezel, A. F., . . . Bardeesy, N. (2016). Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-15-1442

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.